Remimazolam is a novel short-acting benzodiazepine that can be rapidly activated and eliminated, resulting in anterograde amnesia and specific antagonists. Clinical studies have shown that remimazolam has slight inhibition on respiratory and circulatory system, little dependence on liver and kidney function, and almost no injection pain, it is suitable for sedation/anesthesia outside the operating room, general anesthesia inside the operating room and regional block-assisted sedation. It may also have a good application prospect in the fields of ICU sedation. The clinical pharmacology, clinical application, adverse drug reactions, prevention and treatment, and precautions of remimazolam are discussed in this expert guidance to guide its safe and effective use in clinical practice.